» Articles » PMID: 11128604

Cytokines in Parkinson's Disease

Overview
Date 2000 Dec 29
PMID 11128604
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

We found that in Parkinson's disease (PD) the levels of various cytokines [tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-2, IL-4, IL-6, epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, TGF-beta1] were significantly increased in the striatum (caudate and putamen) of the postmortem brain and in ventricular or spinal cerebrospinal fluid (VCSF, LCSF). Furthermore, the levels of the apoptosis-related proteins such as bcl-2 and soluble Fas (sFas) in the striatum were also elevated in PD. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonism mice, the levels of IL-1beta in the striatum were significantly increased, but those of nerve growth factor (NGF) were significantly decreased, compared with control mice. In hemiparkinsonism rats produced by injection of 6-hydroxydopamine (6-OHDA) into one side of the median forebrain bundle, the levels of TNF-alpha in the 6-OHDA-treated side were increased in the striatum and substantia nigra, but not in the cerebral cortex, compared with those in the control side. Repeated administration of L-DOPA in the 6-OHDA-treated rats did not change the TNF-alpha levels in the control side and in the 6-OHDA-treated side in the substantia nigra, striatum, and cerebral cortex. Our results suggest that the changes in the levels of cytokines, neurotrophins, and apoptosis-related proteins in the nigrostriatal regions of PD may be involved in apoptosis and degeneration of the nigrostriatal DA neurons.

Citing Articles

A Comprehensive Review on Utilizing Human Brain Organoids to Study Neuroinflammation in Neurological Disorders.

Rubio A, Hamilton L, Bausch M, Jin M, Papetti A, Jiang P J Neuroimmune Pharmacol. 2025; 20(1):23.

PMID: 39987404 PMC: 11846768. DOI: 10.1007/s11481-025-10181-x.


A single-cell transcriptome analysis reveals astrocyte heterogeneity and identifies CHI3L1 as a diagnostic biomarker in Parkinson's disease.

Gong Z, Guo D, Lin Y, Liu Z, Lv M, Liu X Heliyon. 2025; 11(3):e42051.

PMID: 39931480 PMC: 11808505. DOI: 10.1016/j.heliyon.2025.e42051.


A pilot randomized clinical trial examining the effects of Qigong on inflammatory status and sleep quality in people with Parkinson's disease.

Moon S, Sarmento C, Smirnova I, Colgrove Y, Lai S, Lyons K J Bodyw Mov Ther. 2024; 40:1002-1007.

PMID: 39593404 PMC: 11602653. DOI: 10.1016/j.jbmt.2024.07.025.


Effects of (L.) DC. and Levodopa in Improving Parkinson's Disease in Rotenone Intoxicated Mice.

Zaigham S, Paeng D Curr Issues Mol Biol. 2024; 46(8):9234-9244.

PMID: 39194762 PMC: 11352533. DOI: 10.3390/cimb46080545.


Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications.

Mayer C, Riera-Ponsati L, Kauppinen S, Klitgaard H, Erler J, Hansen S Front Pharmacol. 2024; 15:1437939.

PMID: 39119604 PMC: 11306042. DOI: 10.3389/fphar.2024.1437939.